Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.

ABSTRACT:

Purpose

Although uncommon, detection of BRAF V600E mutations in adult patients with glioblastoma has become increasingly relevant given the widespread application of molecular diagnostics and encouraging therapeutic activity of BRAF/MEK inhibitors.

Methods

We performed a retrospective study of adult glioblastoma patients treated at Dana-Farber Cancer Institute/Brigham and Women's Hospital or Massachusetts General Hospital from January 2011 to July 2019 with an identified BRAF V600E mutation by either immunohistochemistry or molecular testing. Patient characteristics, molecular genomics, and preoperative MRI were analyzed.

Results

Nineteen glioblastoma patients were included, with median age at diagnosis of 41-years-old (range 22-69). Only 1/18 was IDH1/2-mutant; 10/17

SUBMITTER: Lim-Fat MJ 

PROVIDER: S-EPMC8415171 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature